You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

single chemotherapy agent

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Lung Cancer, NSCLC Trial (Lorlatinib, Cisplatin or Carboplatin, Pemetrexed)

Not yet recruiting
  • Lung Cancer
  • Non-small Cell Lung Cancer
  • (no location specified)
Jul 7, 2023

Rectal Cancer Trial (Trifluridine/Tipiracil, intensity-modulated radiotherapy)

Not yet recruiting
  • Rectal Cancer
  • (no location specified)
Jul 27, 2023

Non-Squamous NSCLC (NSCLC), Adenocarcinoma of the Lung, Lung Cancer Trial in United States (Docetaxel, Nivolumab, Gemcitabine)

Terminated
Has Results
  • Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
  • +3 more
  • Anderson, Indiana
  • +8 more
Jul 7, 2022

Metastatic Triple Negative Breast Cancer Trial (pembrolizumab, capecitabine, eribulin)

Completed
Has Results
  • Metastatic Triple Negative Breast Cancer
  • pembrolizumab
  • +4 more
  • (no location specified)
Nov 9, 2021

NSCLC, EGF-R Positive NSCLC Trial in Wuxi (Parimparib, Chemotherapy drug, Targeted Therapy Agent)

Recruiting
  • Carcinoma, Non-Small-Cell Lung
  • EGF-R Positive Non-Small Cell Lung Cancer
  • Wuxi, Jiangsu, China
    Affiliated Hospital of Jiangnan University
Jan 30, 2023

Acute Lymphoblastic Leukemia Trial in Tampa (Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy), Calaspargase

Recruiting
  • Acute Lymphoblastic Leukemia
  • Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy)
  • +2 more
  • Tampa, Florida
    Moffitt Cancer Center
Oct 12, 2022

Head and Neck Squamous Cell Carcinoma Trial in Guangzhou (Capecitabine)

Recruiting
  • Head and Neck Squamous Cell Carcinoma
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
Feb 15, 2022

Solid Tumor, Adult Trial in Belgium, United Kingdom, United States (EOS100850, Pembrolizumab, Chemotherapy)

Recruiting
  • Solid Tumor, Adult
  • Hackensack, New Jersey
  • +4 more
Jun 27, 2022

Colorectal Cancer Trial in Shanghai (SI-B001, Irinotecan, FOLFIRI Protocol)

Recruiting
  • Colorectal Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Dec 16, 2021

MDS, Acute Myeloid Leukemia Trial in France (BST-236)

Recruiting
  • Myelodysplastic Syndromes
  • Acute Myeloid Leukemia
  • Amiens, France
  • +16 more
Jan 2, 2023

NSCLC Trial in Rochester (Pembrolizumab, Pemetrexed (Chemotherapy), Nab-paclitaxel (Chemotherapy))

Recruiting
  • Non-small Cell Lung Cancer
  • Rochester, New York
  • +1 more
Jan 4, 2022

Tumors Trial in China (Atezolizumab, Gemcitabine, Cisplatin)

Active, not recruiting
  • Neoplasms
  • Beijing, China
  • +6 more
Jul 20, 2022

Non-small-cell Lung Cancer Patients Trial in Roma (Durvalumab, Olaparib tablet, Single-agent chemo)

Recruiting
  • Non-small-cell Lung Cancer Patients
  • Roma, RM, Italy
    Istituti Fisioterapici Ospitalieri- Ifo - Istituto Regina Elena
Sep 30, 2022

Mesothelioma, Malignant, Mesothelioma, Malignant Pleural, Mesothelioma Malignant Advanced Trial in Beijing

Not yet recruiting
  • Mesothelioma, Malignant
  • +2 more
  • Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Dec 27, 2021

Non Small Cell Lung Cancer, Advanced Lung Non-Small Cell Carcinoma, PD-L1 Gene Mutation Trial (Pembrolizumab, Pemetrexed,

Withdrawn
  • Non Small Cell Lung Cancer
  • +2 more
  • (no location specified)
Mar 14, 2022

AML, Adult, MDS, Relapse/Recurrence Trial in United States (BST-236)

Recruiting
  • AML, Adult
  • +3 more
  • Shreveport, Louisiana
  • +3 more
Jul 19, 2022

Colorectal Cancer Trial in Belgium, Czechia (GM102, Trifluridine/Tipiracil, GM102 expansion)

Completed
  • Colorectal Cancer
  • Brussels, Belgium
  • +4 more
Apr 11, 2022

Metastatic Colorectal Cancer Trial in Seoul (intra-arterial oxaliplatin + Systemic FOLFIRI + target agent (bevacizumab or

Recruiting
  • Metastatic Colorectal Cancer
  • intra-arterial oxaliplatin + Systemic FOLFIRI + target agent (bevacizumab or cetuximab) every 2 weeks
  • IV FOLFIRI+ target agent (bevacizumab or cetuximab) every 2 weeks
  • Seoul, Korea, Republic of
    Severance Hospital, Yonsei University Health System
Nov 1, 2021

Mesothelioma Trial in United States (pevonedistat, Pemetrexed and cisplatin)

Active, not recruiting
  • Mesothelioma
  • Basking Ridge, New Jersey
  • +7 more
Sep 12, 2022

Metastatic NSCLC, Recurrent NSCLC, Advanced Non-Small Cell Squamous Lung Cancer Trial in Nanjing (Sintilimab + Anlotinib +

Recruiting
  • Metastatic NSCLC
  • +2 more
  • Sintilimab + Anlotinib + Pemetrexed + Cisplatin or Carboplatin
  • Sintilimab + Anlotinib + Albumin Paclitaxel + Carboplatin
  • Nanjing, Jiangsu, China
    The First Affiliated Hospital of Nanjing Medical University
Aug 10, 2021

Esophageal Carcinoma, Esophagogastric Junction Carcinoma Trial in China (pembrolizumab, paclitaxel, docetaxel)

Completed
Has Results
  • Esophageal Carcinoma
  • Esophagogastric Junction Carcinoma
  • pembrolizumab
  • +3 more
  • Hefei, Anhui, China
  • +22 more
Aug 16, 2022

Metastatic Sarcoma Trial in Boston (PM01183, Doxorubicin, Gemcitabine)

Completed
Has Results
  • Metastatic Sarcoma
  • Boston, Massachusetts
  • +1 more
Feb 9, 2021

Previously Untreated Pancreatic Ductal Adenocarcinoma, Relapsed/Refractory Pancreatic Ductal Adenocarcinoma Trial in United

Terminated
Has Results
  • Previously Untreated Pancreatic Ductal Adenocarcinoma
  • Relapsed/Refractory Pancreatic Ductal Adenocarcinoma
  • Scottsdale, Arizona
  • +8 more
Mar 31, 2021

Triple Negative Breast Cancer, Neoadjuvant Chemo, Pembrolizumab Trial in Seoul (Visium, Whole Genome Sequencing(WGS)/Whole

Recruiting
  • Triple Negative Breast Cancer
  • +3 more
  • Visium, Whole Genome Sequencing(WGS)/Whole Transcriptome Sequencing(WTS)
  • Seoul, Korea, Republic of
    Samsung Medical Center
Jun 15, 2023

NHL, Multiple Myeloma, Blood Cancer Trial in Minneapolis, Houston, Fairfax (IDP-023, Rituximab, Daratumumab)

Recruiting
  • NHL
  • +6 more
  • Minneapolis, Minnesota
  • +2 more
Nov 7, 2023